|Mr. Ashleigh Palmer B.Sc., M.B.A.||Co-Founder, Pres, CEO & Director||583.5k||N/A||1963|
|Mr. Francisco Leon M.D., Ph.D.||Co-Founder & Chief Scientific Officer||564.5k||N/A||1972|
|Mr. Andrew T. Drechsler||Chief Financial Officer||499k||N/A||1972|
|Dr. Eleanor L. Ramos||Chief Medical Officer & COO||534.62k||N/A||1956|
|Dr. Sherron Kell||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-300, an anti-TLR3 mAb, which is in Phase Ib clinical trial for the treatment of ulcerative colitis; PRV-3279, which is in phase Ib/IIa for the treatment of lupus; PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D; and PRV-015, which is in phase IIb for the treatment of gluten-free diet non-responding celiac disease. The company has a licensing and co-development agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.
Provention Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.